Takeda invests $230M expanding plasma-derived therapies capacity in Los Angeles

Takeda announced a $230 million investment to expand production capacity for plasma-derived therapies at its Los Angeles manufacturing site, creating over 125 new long-term jobs.

“We are pleased to make this investment at our LA site, demonstrating our commitment to our manufacturing footprint in the U.S.”takeda.com

• 1 source
• takeda.comTakeda Invests 230 Million US Dollars in Expanding Production Capacity for Plasma-Derived Therapies at Los Angeles Manufacturing SiteTakeda Pharmaceutical Company LimitedJun 11, 2024

Summarized from public sources; check the original articles before acting on it.